South Dakota 2025 Regular Session

South Dakota Senate Bill SB35 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1		-	25.232.16 100th Legislative Session 35
	1	+	25.232.15 100th Legislative Session 35
2	2
3	3
4	4		2025 South Dakota Legislature
5	5		Senate Bill 35
6		-	ENROLLED
7		-
8		-	AN ACT
9		-
10		-
11		-	ENTITLED An Act to modify substances listed on the controlled substances schedule
12		-	and to declare an emergency.
13		-	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA:
14		-	Section 1. That § 34-20B-13 be AMENDED:
15		-	34-20B-13. Any of the following opium derivatives and opiates, their salts,
16		-	isomers, esters, ethers, and salts of isomers, esters, and ethers, is included in Schedule
17		-	I, unless specifically excepted, whenever the existence of the salts, isomers, esters,
18		-	ethers, and salts of isomers, esters, and ethers is possible within the specific chemical
19		-	designation:
20		-	(1) Acetylcodone;
21		-	(2) Benzylmorphine;
22		-	(3) Codeine methylbromide;
23		-	(4) Codeine-N-Oxide;
24		-	(5) Desomorphine;
25		-	(6) Drotebanol;
26		-	(7) Heroin;
27		-	(8) Hydromorphinol;
28		-	(9) Methyldesorphine;
29		-	(10) Methylhydromorphine;
30		-	(11) Morphine methylbromide;
31		-	(12) Morphine methylsulfonate;
32		-	(13) Morphine-N-Oxide;
33		-	(14) Myrophine;
34		-	(15) Nicocodeine;
35		-	(16) Nicomorphine;
36		-	(17) Normorphine; 25.232.16 2 35
37		-	SB35 ENROLLED
38		-	(18) Thebacon;
39		-	(19) 3-Methylfentanyl;
40		-	(20) Fentanyl analogs. Any substituted derivatives of fentanyl unless specifically
41		-	excepted, listed in another schedule, or contained within a pharmaceutical product
42		-	approved by the United States Food and Drug Administration, that is structurally
43		-	related to fentanyl by modification in any one or more of the following ways:
44		-	(a) By replacement of the phenyl portion of the phenethyl group by any
45		-	monocycle whether or not further substituted in or on the monocycle;
46		-	(b) By substitution in or on or replacement of the phenethyl group with alkyl,
47		-	alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
48		-	(c) By substitution in or on the piperadine ring with alkyl, alkenyl, alkoxyl,
49		-	ester, ether, hydroxyl, halo, haloalkyl, amino, phenyl, substituted phenyl,
50		-	or nitro groups;
51		-	(d) By replacement of the aniline ring with any aromatic monocycle whether or
52		-	not further substituted in or on the aromatic monocycle; or
53		-	(e) By the replacement of the N-propionyl group by another acyl group.
54		-	Some trade and other names: N -(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl
55		-	fentanyl); N -(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl
56		-	fentanyl); N -(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl,
57		-	acryloylfentanyl); N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-
58		-	fluorofentanyl or 2 -fluorofentanyl); N -(1-phenethylpiperidin-4-yl)-N-
59		-	phenyltetrahydrofuran-2-carboxamide (tetrahydrofuranyl fentanyl); 2 -methoxy-N-(1-
60		-	phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl fentanyl); N -(1-
61		-	phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (cyclopropyl fentanyl), N -
62		-	phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide (valeryl fentanyl); N -(1-
63		-	phenethylpiperidin-4-yl)-N-phenylbutyramide (butyrl fen tanyl); N-[1-(2-hydroxy-2-
64		-	thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide (Beta-Hydroxythiofentanyl); N-
65		-	(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para -fluorobutyryl
66		-	fentanyl); N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para-
67		-	methoxybutyryl fentanyl); N -(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
68		-	yl)isobutyramide (para-chloroisobutyryl fentanyl); N-(1-phenethylpiperidin-4-yl)-N-
69		-	phenylisobutyramide (isobutyryl fentanyl); N -(1-phenethylpiperidin-4-yl)-N-
70		-	phenylcyclopentanecarboxamide (cyclopentyl fentanyl); N -(2-fluorophenyl)-2-methoxy-
71		-	N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil); N -(4-fluorophenyl)-N-(1- 25.232.16 3 35
72		-	SB35 ENROLLED
73		-	phenethylpiperidin-4-yl)isobutyramide (para-fluoroisobutyryl fentanyl); (E) -N-(1-
74		-	phenethylpiperidin-4-yl)-N-phenylbut-2-enamide (Crotonyl fentanyl);
75		-	(21) 1-Methyl-4-phenyl-4-propionoxypiperidine;
76		-	(22) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine;
77		-	(23) 3,4-dichloro-N[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700);
78		-	(24) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45);
79		-	(25) 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide (AH -7921);
80		-	(26) 2-(2,4-dichlorophenyl)-N-2-(dimethylamino)cyclohexyl)-N-methylacetamide (U -
81		-	48800);
82		-	(27) Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (U -
83		-	49900);
84		-	(28) N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide
85		-	(Methylenedioxy-U-47700);
86		-	(29) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropylbenzamide (Isopropyl-
87		-	U-47700);
88		-	(30) 1-(1,2-Diphenylethyl)piperidine (Diphenidine);
89		-	(31) N-Ethyl-1,2-diphenylethylamine (Ephenidine);
90		-	(32) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-
91		-	2-one (Brorphine);
92		-	(33) 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol)
93		-	(Zipeprol); and
94		-	(34) 2-Methyl AP-237 (1Methyl-4(3Phenylprop-2-en-1-yl)Piperizin-1-yl)Butan-1-one).
95		-	Section 2. That § 34-20B-14 be AMENDED:
96		-	34-20B-14. Any material, compound, mixture, or preparation that contains any
97		-	quantity of the following hallucinogenic substances, their salts, isomers, and salts of
98		-	isomers, is included in Schedule I, unless specifically excepted, whenever the existence of
99		-	such salts, isomers, and salts of isomers is possible within the specific chemical
100		-	designation:
101		-	(1) Bufotenine;
102		-	(2) Diethyltryptamine (DET);
103		-	(3) Dimethyltryptamine (DMT);
104		-	(4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT);
105		-	(5) 5-methoxy-3, 4-methylenedioxy amphetamine;
106		-	(6) 4-bromo-2, 5-dimethoxyamphetamine; 25.232.16 4 35
107		-	SB35 ENROLLED
108		-	(7) 4-methoxyamphetamine;
109		-	(8) 4-methoxymethamphetamine;
110		-	(9) 4-methyl-2, 5-dimethoxyamphetamine;
111		-	(10) Hashish and hash oil;
112		-	(11) Ibogaine;
113		-	(12) Lysergic acid diethylamide;
114		-	(13) Mescaline;
115		-	(14) N-ethyl-3-piperidyl benzilate;
116		-	(15) N-methyl-3-piperidyl benzilate;
117		-	(16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP);
118		-	(17) Peyote, except that when used as a sacramental in services of the Native American
119		-	church in a natural state which is unaltered except for drying or curing and cutting
120		-	or slicing, it is hereby excepted;
121		-	(18) Psilocybin;
122		-	(19) Psilocyn;
123		-	(20) Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in
124		-	§ 38-35-1; in a drug product approved by the United States Food and Drug
125		-	Administration; or marijuana in its natural and unaltered state; including any
126		-	compound, except nabilone or compounds listed under a different schedule,
127		-	structurally derived from 6,6Ν dimethyl-benzo[c]chromene by substitution at the
128		-	3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups,
129		-	whether or not the compound is further modified in any of the following ways:
130		-	(a) By partial to complete saturation of the C-ring; or
131		-	(b) By substitution at the 1-position with a hydroxyl or methoxy group; or
132		-	(c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl
133		-	group; or
134		-	(d) By modification of the possible 3-alkyl group with a 1,1Ν dimethyl moiety, a
135		-	1,1Ν cyclic moiety, an internal methylene group, an internal acetylene
136		-	group, or a terminal halide, cyano, azido, or dimethylcarboxamido group.
137		-	Some trade and other names: JWH -051; JWH-057; JWH-133; JWH-359; HHC; AM-
138		-	087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243;
139		-	HU-336;
140		-	(21) 3, 4, 5-trimethoxy amphetamine;
141		-	(22) 3, 4-methylenedioxy amphetamine;
142		-	(23) 3-methoxyamphetamine; 25.232.16 5 35
143		-	SB35 ENROLLED
144		-	(24) 2, 5-dimethoxyamphetamine;
145		-	(25) 2-methoxyamphetamine;
146		-	(26) 2-methoxymethamphetamine;
147		-	(27) 3-methoxymethamphetamine;
148		-	(28) Phencyclidine;
149		-	(29) 3, 4-methylenedioxymethamphetamine (MDMA);
150		-	(30) 3, 4-methylenedioxy-N-ethylamphetamine;
151		-	(31) N-hydroxy-3, 4-methylenedioxyamphetamine;
152		-	(32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline);
153		-	(33) 2,5 Dimethoxy-4-ethylamphetamine;
154		-	(34) N,N-Dimethylamphetamine;
155		-	(35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine;
156		-	(36) Aminorex;
157		-	(37) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-
158		-	oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
159		-	(38) Cathinone and other variations, defined as any compound, material, mixture,
160		-	preparation or other product unless listed in another schedule or an approved FDA
161		-	drug, structurally derived from 2-aminopropan-1-one by substitution at the 1-
162		-	position with either phenyl, naphthyl, or thiophene ring systems, whether or not
163		-	the compound is further modified in any of the following ways:
164		-	(a) By substitution in the ring system to any extent with alkyl, alkylenedioxy,
165		-	alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further
166		-	substituted in the ring system by one or more other univalent substitutents;
167		-	(b) By substitution at the 3-position with an acyclic alkyl substituent; or
168		-	(c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
169		-	methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a
170		-	cyclic structure.
171		-	Some trade or other names: methcathinone, 4 -methyl-N-methylcathinone
172		-	(mephedrone); 3,4 -methylenedioxy-N-methylcathinone (methylone); 3,4 -
173		-	methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4 -
174		-	flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk-
175		-	PMMA); Ethcathinone (N -Ethylcathinone); 3,4-methylenedioxyethcathinone
176		-	(ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N -
177		-	dimethylcathinone (metamfepramone); Alpha -pyrrolidinopropiophenone (alpha-
178		-	PPP); 4 -methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4 - 25.232.16 6 35
179		-	SB35 ENROLLED
180		-	methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha -
181		-	pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4Ν-Methyl-alpha-
182		-	pyrrolidinobutiophenone (MPBP); Methyl -α-pyrrolindinopropiophenone (MPPP);
183		-	Methyl-α-pyrrolidino-hexanophenone (MPHP); Bu phedrone; Methyl -N-
184		-	ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC);
185		-	Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC);
186		-	Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl -
187		-	alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy-
188		-	alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC);
189		-	Methylbuphedrone (MBP); Benzedrone (4 -MBC); Dibutylone (DMBDB);
190		-	Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N -ethyl-N-
191		-	Methylcathinone; N -ethylbuphedrone, 1 -(1,3-benzodioxol-5-yl)2-
192		-	(ethylamino)pentan-1-one (N -Ethylpentylone); 4' -Methyl-alpha-
193		-	pyrrolidinopropiophenone (4 -MEPPP, MPPP or MαPPP); alpha -
194		-	Pyrrolidinobutiophenone (α -PBP); 1 -(1,3-benzodioxol-5-yl)-2-(tert-
195		-	butylamino)propan-1-one (Ter tylone); 1 -(1,3-benzodioxol-5-yl)-2-
196		-	(ethylamino)hexan-1-one (N-ethyl Hexylone); 1 -(1,3-benzodioxol-5-yl)-2-
197		-	(methylamino)pntan-1-one (Pentylone); N -ethylhexedrone (α
198		-	ethylaminohexanophenone); alpha -pyrrolidinohexanophenone (α-PHP); 4-methyl-
199		-	alpha-ethylaminopentiophenone (4 -MEAP); 4′ -methyl-alpha-
200		-	pyrrolidinohexiophenone (MPHP); alpha -pyrrolidinoheptaphenone (PV8); 4′ -
201		-	chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP); Alpha-PIHP (4-methyl-
202		-	1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one;
203		-	(39) 2,5-Dimethoxy-4-ethylamphetamine (DOET);
204		-	(40) Alpha-ethyltryptamine;
205		-	(41) 4-Bromo-2,5-dimethoxy phenethylamine;
206		-	(42) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
207		-	(43) 1-(3-trifluoromethylphenyl) piperazine (TFMPP);
208		-	(44) Alpha-methyltryptamine (AMT);
209		-	(45) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
210		-	(46) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
211		-	(47) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is
212		-	not listed as a controlled substance in another schedule, is not an FDA-approved
213		-	drug, and contains any quantity of the following substances, their salts, isomers
214		-	(whether optical, positional, or geometric), homologues, modifications of the indole 25.232.16 7 35
215		-	SB35 ENROLLED
216		-	ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog
217		-	substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or
218		-	propionaldehyde structure, and salts of isomers, homologues, and modifications,
219		-	unless specifically excepted, whenever the existence of these salts, isomers,
220		-	homologues, modifications, and salts of isomers, homologues, and modifications is
221		-	possible within the specific chemical designation:
222		-	(a) Naphthoylindoles. Any compound containing a 2 -(1- naphthoyl)indole or 3-
223		-	(1-naphthoyl)indole structure with substitution at the nitrogen atom of the
224		-	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
225		-	1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-
226		-	(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
227		-	(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
228		-	further substituted on the indole ring to any extent and whether or not
229		-	substituted on the naphthyl ring to any extent.
230		-	Some trade or other names: JWH -015; 1-pentyl-3-(1-naphthoyl)indole
231		-	(JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-
232		-	naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole
233		-	(JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-
234		-	morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398;
235		-	1-pentyl-3-(1-naphthoyl)indole (AM -678); 1 -(5-fluoropentyl)-3-(1-
236		-	naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009;
237		-	JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048;
238		-	JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079;
239		-	JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120;
240		-	JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182;
241		-	JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234;
242		-	JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262;
243		-	JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400;
244		-	JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220;
245		-	AM-1221; AM-1235; AM-2232, THJ-2201;
246		-	(b) Naphthylmethylindoles. Any compound containing a 1H -indol-2-yl-(1-
247		-	naphthyl)methane or 1H -indol-3-yl-(1-naphthyl)methane structure with
248		-	substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
249		-	alkenyl, cycloalkylmethyl, cycloalkyleth yl, 1 -(N-methyl-2-
250		-	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1 -(N-methyl-2- 25.232.16 8 35
251		-	SB35 ENROLLED
252		-	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-
253		-	4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted
254		-	on the indole ring to any extent and whether or not substituted on the
255		-	naphthyl ring to any extent.
256		-	Some trade or other names: JWH -175; JWH-184; JWH-185; JWH-192;
257		-	JWH-194; JWH-195; JWH-196; JWH-197; JWH-199;
258		-	(c) Phenylacetylindoles. Any compound containing a 2-phenylacetylindole or 3-
259		-	phenylacetylindole structure with substitution at the nitrogen atom of the
260		-	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
261		-	1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-
262		-	(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
263		-	(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
264		-	further substituted on the indole ring to any extent and whether or not
265		-	substituted on the phenyl ring to any extent.
266		-	Some trade or other names: 1 -cyc lohexylethyl-3-(2-
267		-	methoxyphenylacetyl)indole (SR -18); 1 -cyclohexylethyl-3-(2-
268		-	methoxyphenylacetyl)indole (RCS -8); 1 -pentyl-3-(2-
269		-	methoxyphenylacetyl)indole (JWH -250); 1 -pentyl-3-(2-
270		-	chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-
271		-	204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-
272		-	248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-
273		-	305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-
274		-	316; Cannabipiperidiethanone;
275		-	(d) Benzoylindoles. Any compound containing a 2 -(benzoyl)indole or 3-
276		-	(benzoyl)indole structure with substitution at the nitrogen atom of the
277		-	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
278		-	1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-
279		-	(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
280		-	(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not
281		-	further substituted on the indole ring to any extent and whether or not
282		-	substituted on the phenyl ring to any extent.
283		-	Some trade or other names: 1 -(5-fluoropentyl)-3-(2-iodobenzoyl)indole
284		-	(AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline
285		-	(WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630;
286		-	AM-661; AM-2233; AM-1241; 25.232.16 9 35
287		-	SB35 ENROLLED
288		-	(e) Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-
289		-	(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
290		-	pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
291		-	cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
292		-	cyanoalky, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
293		-	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl
294		-	group, whether or not further substituted on the pyrrole ring to any extent
295		-	and whether or not substituted on the naphthyl ring to any extent.
296		-	Some trade or other names: JWH -307; JWH-030; JWH-031; JWH-145;
297		-	JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244;
298		-	JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346;
299		-	JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369;
300		-	JWH-370; JWH-371; JWH-373; JWH-392;
301		-	(f) Naphthylmethylindenes. Any compound containing a naphthylideneindene
302		-	structure with substitution at the 3-position of the indene ring by an alkyl,
303		-	haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-
304		-	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-(N-methyl-2-
305		-	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-
306		-	4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted
307		-	on the indene ring to any extent and whether or not substituted on the
308		-	naphthyl ring to any extent.
309		-	Some trade or other names: JWH-171; JWH-176; JWH-220;
310		-	(g) Cyclohexylphenols. Any compound containing a 2 -(3-
311		-	hydroxycyclohexyl)phenol structure with substitution at the 5-position of
312		-	the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
313		-	cycloalkylethyl, 1 -(N-methyl-2-piperidinyl)methyl, or 2 -(4-
314		-	morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
315		-	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl
316		-	group, whether or not substituted on the cyclohexyl ring to any extent.
317		-	Some trade or other names: 5 -(1,1-dimethylheptyl)-2-[(1R,3S)-3-
318		-	hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes
319		-	C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667;
320		-	(h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
321		-	6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names:
322		-	HU-210; 25.232.16 10 35
323		-	SB35 ENROLLED
324		-	(i) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3 -de]-1,4-
325		-	benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-
326		-	2;
327		-	(j) Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-
328		-	acetyl indole structure substituted at the acetyl by replacement of the
329		-	methyl group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or
330		-	propionaldehyde substituent whether or not further substituted on the
331		-	tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde
332		-	substituent to any extent and whether or not further substituted at the
333		-	nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
334		-	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
335		-	morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
336		-	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl
337		-	group whether or not further substituted on the indole ring to any extent.
338		-	Some trade and or names: (1 -Pentylindol-3-yl)-(2,2,3,3-
339		-	tetramethylcyclopropyl)methanone (UR -144); (1-(5-fluoropentyl)indol-3-
340		-	yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR -11); (1 -(2-
341		-	morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-
342		-	tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-
343		-	yl)methyl]-3-(adamant-1-oyl)indole (AM -1248); 1 -Pentyl-3-(1-
344		-	adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (1-
345		-	(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
346		-	tetramethylcyclopropyl)methanone (FUB -144);
347		-	(k) Substituted Carboxamide Indole. Any compound containing a 2 -carboxamide
348		-	indole or 3-carboxamide indole structure substituted at the nitrogen of the
349		-	carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl,
350		-	phenyl, or propionaldehyde substituent, whether or not further substituted
351		-	on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or
352		-	propionaldehyde substituent to any extent and whether or not further
353		-	substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
354		-	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-
355		-	piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-
356		-	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-
357		-	4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted
358		-	on the indole ring to any extent. 25.232.16 11 35
359		-	SB35 ENROLLED
360		-	Some trade and other names: JWH -018 adamantyl carboxamide; STS -135;
361		-	MN-18; 5-Fluoro-MN-18, 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
362		-	pyrrolo[2,3-b]pyridine-3-carboxamide (5F -CUMYL-P7AICA) ; N -
363		-	(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F -
364		-	APINACA); methyl (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-
365		-	3,3-dimethylbutanoate (5F-ADB); N-(1-amino-3-methyl-1-oxobutan-2-yl)-
366		-	1-(cyclohexylmethyl)indazole-3-carboxamide (AB -CHMINACA); 1 -(4-
367		-	cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN-
368		-	CUMYL-BUTINACA); N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
369		-	(cyclohexylmethyl)indazole-3-carboxamide (ADB -CHMINACA or MAB -
370		-	CHMINACA); methyl (2S) -2-[[1-[4-fluorophenyl)methyl]indazole-3-
371		-	carbonyl]amino]-3,3-dimethylbutanoate (MDMB -FUBINACA); methyl 2-(1-
372		-	(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB -
373		-	CHMICA); methyl (2S) -2-[[1-[4-fluorophenyl)methyl]indazole-3-
374		-	carbonyl]amino]-3-methylbutanoate (AMB -FUBINACA); Methyl 2 -(1-(5-
375		-	fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
376		-	methyl 2 -(1-(5-fluoropentyl-1Hindole-3-carboxamido)-3,3-
377		-	dimethylbutaoate (5F-MDMB-PICA); methyl (S)-3,3-dimethyl-2-[(1-(pent-
378		-	4-enlindazole-3-carbonyl)amino]butanoate (MDMB -4en-PINACA); methyl
379		-	2-(1-(4-fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate
380		-	(4F-MDMB-BUTINACA); Ethyl 2 -(1-(5-fluoropentyl)-1H-indazole-3-
381		-	carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PINACA); Methyl 2-(1-(5-
382		-	fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate S(5F -
383		-	MDMB-PICA); N -(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
384		-	carboxamide (FUB-APINACA); 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-
385		-	1H-indazole-3-carboxamide (5F-CUMYL-PINACA);
386		-	(l) Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-
387		-	carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl
388		-	group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl,
389		-	cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent
390		-	whether or not further substituted on the phenyl, benzyl, naphthyl,
391		-	adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde
392		-	substituent to any extent and whether or not further substituted at the
393		-	nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
394		-	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4- 25.232.16 12 35
395		-	SB35 ENROLLED
396		-	morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
397		-	morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group
398		-	whether or not further substituted on the indole ring to any extent.
399		-	Some trade and other names: Naphthalen-1-yl 1-(5-fluoropntyl)-1H-indole-
400		-	3-carboxylate (NM2201);
401		-	(48) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);
402		-	(49) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
403		-	(50) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
404		-	(51) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C -C);
405		-	(52) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C -I);
406		-	(53) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C -T-2);
407		-	(54) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C -T-4);
408		-	(55) 2-(2,5-Dimethoxyphenyl)ethanamine (2C -H);
409		-	(56) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
410		-	(57) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
411		-	(58) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a
412		-	controlled substance in another schedule or an approved FDA drug, structurally
413		-	derived from phenylethan-2-amine by substitution on the phenyl ring in any of the
414		-	following ways: by substitution with a fused methylenedioxy, fused furan, or fused
415		-	tetrahydrofuran ring system; by substitution with two alkoxy groups; by
416		-	substitution with one alkoxy and either one fused furan, tetrahydrofuran, or
417		-	tetrahydropyran ring system; by substitution with two fused ring systems from any
418		-	combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems;
419		-	whether or not the compound is further modified in any of the following ways:
420		-	(a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl,
421		-	trifluoromethyl, alkoxy, or alkylthio groups;
422		-	(b) By substitution on the 2-position by any alkyl groups; or
423		-	(c) By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl,
424		-	benzyl, methoxybenzyl, or hydroxybenzyl groups.
425		-	Some trade and other names: 2 -(2,5-dimethoxy-4-
426		-	(methylthio)phenyl)ethanamine (2C -T or 4 -methylthio-2,5-
427		-	dimethoxyphenethylamine); 1 -(2,5-dimethoxy-4-iodophenyl)-propan-2-amine
428		-	(DOI or 2, 5 -Dimethoxy-4-iodoamphetamine); 1 -(4-Bromo-2,5-
429		-	dimethoxyphenyl)-2-aminopropane (DOB or 2,5 -Dimethoxy-4-
430		-	bromoamphetamine); 1 -(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC 25.232.16 13 35
431		-	SB35 ENROLLED
432		-	or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-
433		-	[(2-methoxyphenyl)methyl]ethanamine (2C -B-NBOMe; 25B -NBOMe or 2,5 -
434		-	Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2 -4-iodo-2,5-
435		-	dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethana mine (2C-I-NBOMe; 25I-
436		-	NBOMe or 2,5 -Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N -(2-
437		-	Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline -NBOMe or 3,4,5 -
438		-	trimethoxy-(2-methoxybenzyl)phenethylamine); 2 -(4-chloro-2,5-
439		-	dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C-C-NBOMe; 25C-
440		-	NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2 -(7-
441		-	Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY);
442		-	2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-
443		-	FLY); 2 -(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
444		-	yl)ethanamine (2C -B-butterFLY); -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-
445		-	tetrahydrobenzo[1,2-b:4,5-bΝ]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe);
446		-	1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo -
447		-	benzodifuranyl-isopropylamine or bromo-dragonFLY); -(2-Hydroxybenzyl)-4-iodo-
448		-	2,5-dimethoxyphenethylamine (2C -I-NBOH or 25I -NBOH); 5 -(2-
449		-	Aminoprpyl)benzofuran (5-APB); 6(2-Aminopropyl)benzofuran (6-APB); 5-(2-
450		-	Aminopropyl)-2,3-dihydrobenzofuran (5 -APDB); 6 -(2-Aminopropyl)-2,3,-
451		-	dihydrobenzofuran (6-APDB); para-methoxymethamphetamine (PMMA);
452		-	(59) Substituted tryptamines. Any compound, unless specifically exempt, listed as a
453		-	controlled substance in another schedule or an approved FDA drug, structurally
454		-	derived from 2-(1H-indol-3-yl)ethanamine by mono - or di-substitution of the
455		-	amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen
456		-	atom in a cyclic structure whether or not the compound is further substituted at
457		-	the alpha-position with an alkyl group or whether or not further substituted on the
458		-	indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups.
459		-	Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-
460		-	acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-
461		-	methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-
462		-	HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
463		-	(60) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13);
464		-	(61) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48);
465		-	(62) 1-(4-Fluorophenyl)piperazine (pFPP);
466		-	(63) 1-(3-Chlorophenyl)piperazine (mCPP); 25.232.16 14 35
467		-	SB35 ENROLLED
468		-	(64) 1-(4-Methoxyphenyl)piperazine (pMeOPP);
469		-	(65) 1,4-Dibenzylpiperazine (DBP);
470		-	(66) Isopentedrone;
471		-	(67) Fluoromethamphetamine;
472		-	(68) Fluoroamphetamine;
473		-	(69) Fluorococaine;
474		-	(70) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
475		-	(71) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22);
476		-	(72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-
477		-	PINACA);
478		-	(73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-
479		-	carboxamide (5 Fluoro-AB-PINACA);
480		-	(74) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
481		-	carboxamide (AB-FUBINACA);
482		-	(75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide
483		-	(ADB-PINACA (ADBICA));
484		-	(76) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-
485		-	carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA));
486		-	(77) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
487		-	carboxamide (ADB-FUBINACA);
488		-	(78) N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-
489		-	3-carboxamide (5-Fluoro-3,5-AB-PFUPPYCA); and
490		-	(79) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine).
491		-	Section 3. Whereas, this Act is necessary for the immediate preservation of the public peace,
492		-	health, or safety, an emergency is hereby declared to exist, and this Act shall be in full force
493		-	and effect from and after its passage and approval. 25.232.16 15 35
494		-	SB35 ENROLLED
495		-	An Act to modify substances listed on the controlled substances schedule and to declare an
496		-	emergency.
497		-
498		-
499		-
500		-
501		-	I certify that the attached Act originated in
502		-	the:
503		-
504		-	Senate as Bill No. 35
505		-
506		-
507		-
508		-	Secretary of the Senate
509		-
510		-
511		-
512		-
513		-	President of the Senate
514		-
515		-	Attest:
516		-
517		-
518		-
519		-
520		-	Secretary of the Senate
521		-
522		-
523		-
524		-
525		-	Speaker of the House
526		-
527		-	Attest:
528	6
529	7
530	8
531	9
532	10
533		-	Chief Clerk
534	11
	12	+	Introduced by: The Chair of the Committee on Health and Human Services at the request of the Department of Health
535	13
536		-
537		-	Senate Bill No. 35
538		-	File No. ____
539		-	Chapter No. ______
540		-
541		-
542		-
543		-	Received at this Executive Office
544		-	this _____ day of _____________,
545		-
546		-	2025 at ____________M.
547		-
548		-
549		-
550		-	By
551		-	for the Governor
552		-
553		-
554		-	The attached Act is hereby
555		-	approved this ________ day of
556		-	______________, A.D., 2025
557		-
558		-
559		-
560		-
561		-
562		-	Governor
563		-
564		-	STATE OF SOUTH DAKOTA ,
565		-	ss.
566		-	Office of the Secretary of State
567		-
568		-
569		-	Filed ____________, 2025
570		-	at _________ o'clock __M.
571		-
572		-
573		-
574		-
575		-
576		-	Secretary of State
577		-
578		-
579		-
580		-	By
581		-	Asst. Secretary of State
582		-
583		-
	14	+	Underscores indicate new language.
	15	+	Overstrikes indicate deleted language.
	16	+	An Act to modify substances listed on the controlled substances schedule and to 1
	17	+	declare an emergency. 2
	18	+	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF SOUTH DAKOTA: 3
	19	+	Section 1. That § 34-20B-13 be AMENDED: 4
	20	+	34-20B-13. Any of the following opium derivatives and opiates, their salts, 5
	21	+	isomers, esters, ethers, and salts of isomers, esters, and ethers, is included in Schedule 6
	22	+	I, unless specifically excepted, whenever the existence of such the salts, isomers, esters, 7
	23	+	ethers, and salts of isomers, esters, and ethers is possible within the specific chemical 8
	24	+	designation: 9
	25	+	(1) Acetylcodone; 10
	26	+	(2) Benzylmorphine; 11
	27	+	(3) Codeine methylbromide; 12
	28	+	(4) Codeine-N-Oxide; 13
	29	+	(5) Desomorphine; 14
	30	+	(6) Drotebanol; 15
	31	+	(7) Heroin; 16
	32	+	(8) Hydromorphinol; 17
	33	+	(9) Methyldesorphine; 18
	34	+	(10) Methylhydromorphine; 19
	35	+	(11) Morphine methylbromide; 20
	36	+	(12) Morphine methylsulfonate; 21
	37	+	(13) Morphine-N-Oxide; 22
	38	+	(14) Myrophine; 23
	39	+	(15) Nicocodeine; 24
	40	+	(16) Nicomorphine; 25
	41	+	(17) Normorphine; 26 25.232.15 2 35
	42	+	Underscores indicate new language.
	43	+	Overstrikes indicate deleted language.
	44	+	(18) Thebacon; 1
	45	+	(19) 3-Methylfentanyl; 2
	46	+	(20) Fentanyl analogs. Any substituted derivatives of fentanyl unless specifically 3
	47	+	excepted, listed in another schedule, or contained within a pharmaceutical product 4
	48	+	approved by the United States Food and Drug Administration, that is structurally 5
	49	+	related to fentanyl by modification in any one or more of the following ways: 6
	50	+	(a) By replacement of the phenyl portion of the phenethyl group by any 7
	51	+	monocycle whether or not further substituted in or on the monocycle; 8
	52	+	(b) By substitution in or on or replacement of the phenethyl group with alkyl, 9
	53	+	alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups; 10
	54	+	(c) By substitution in or on the piperadine ring with alkyl, alkenyl, alkoxyl, 11
	55	+	ester, ether, hydroxyl, halo, haloalkyl, amino, phenyl, substituted phenyl, 12
	56	+	or nitro groups; 13
	57	+	(d) By replacement of the aniline ring with any aromatic monocycle whether or 14
	58	+	not further substituted in or on the aromatic monocycle; or 15
	59	+	(e) By the replacement of the N-propionyl group by another acyl group. 16
	60	+	Some trade and other names: N -(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl 17
	61	+	fentanyl); N -(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl 18
	62	+	fentanyl); N -(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl, 19
	63	+	acryloylfentanyl); N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (ortho-20
	64	+	fluorofentanyl or 2 -fluorofentanyl); N -(1-phenethylpiperidin-4-yl)-N-21
	65	+	phenyltetrahydrofuran-2-carboxamide (tetrahydrofuranyl fentanyl); 2 -methoxy-N-(1-22
	66	+	phenethylpiperidin-4-yl)-N-phenylacetamide (methoxyacetyl fentanyl); N -(1-23
	67	+	phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (cyclopropyl fentanyl), N -24
	68	+	phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide (valeryl fentanyl); N -(1-25
	69	+	phenethylpiperidin-4-yl)-N-phenylbutyramide (butyrl fentanyl); N -[1-(2-hydroxy-2-26
	70	+	thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide (Beta-Hydroxythiofentanyl); N-27
	71	+	(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para -fluorobutyryl 28
	72	+	fentanyl); N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide (para-29
	73	+	methoxybutyryl fentanyl); N -(4-chlorophenyl)-N-(1-phenethylpiperidin-4-30
	74	+	yl)isobutyramide (para-chloroisobutyryl fentanyl); N-(1-phenethylpiperidin-4-yl)-N-31
	75	+	phenylisobutyramide (isobutyryl fentanyl); N -(1-phenethylpiperidin-4-yl)-N-32
	76	+	phenylcyclopentanecarboxamide (cyclopentyl fentanyl); N -(2-fluorophenyl)-2-methoxy-33
	77	+	N-(1-phenethylpiperidin-4-yl)acetamide (ocfentanil); N -(4-fluorophenyl)-N-(1-34 25.232.15 3 35
	78	+	Underscores indicate new language.
	79	+	Overstrikes indicate deleted language.
	80	+	phenethylpiperidin-4-yl)isobutyramide (para-fluoroisobutyryl fentanyl); (E) -N-(1-1
	81	+	phenethylpiperidin-4-yl)-N-phenylbut-2-enamide (Crotonyl fentanyl); 2
	82	+	(21) 1-Methyl-4-phenyl-4-propionoxypiperidine; 3
	83	+	(22) 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine; 4
	84	+	(23) 3,4-dichloro-N[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700); 5
	85	+	(24) 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45); 6
	86	+	(25) 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide (AH -7921); 7
	87	+	(26) 2-(2,4-dichlorophenyl)-N-2-(dimethylamino)cyclohexyl)-N-methylacetamide (U -8
	88	+	48800); 9
	89	+	(27) Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (U -10
	90	+	49900); 11
	91	+	(28) N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide 12
	92	+	(Methylenedioxy-U-47700); 13
	93	+	(29) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropylbenzamide (Isopropyl-14
	94	+	U-47700); 15
	95	+	(30) 1-(1,2-Diphenylethyl)piperidine (Diphenidine); 16
	96	+	(31) N-Ethyl-1,2-diphenylethylamine (Ephenidine); 17
	97	+	(32) 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-18
	98	+	2-one (Brorphine); and 19
	99	+	(33) 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol) 20
	100	+	(Zipeprol); and 21
	101	+	(34) 2-Methyl AP-237 (1Methyl-4(3Phenylprop-2-en-1-yl)Piperizin-1-yl)Butan-1-one). 22
	102	+	Section 2. That § 34-20B-14 be AMENDED: 23
	103	+	34-20B-14. Any material, compound, mixture, or preparation that contains any 24
	104	+	quantity of the following hallucinogenic substances, their salts, isomers, and salts of 25
	105	+	isomers, is included in Schedule I, unless specifically excepted, whenever the existence of 26
	106	+	such salts, isomers, and salts of isomers is possible within the specific chemical 27
	107	+	designation: 28
	108	+	(1) Bufotenine; 29
	109	+	(2) Diethyltryptamine (DET); 30
	110	+	(3) Dimethyltryptamine (DMT); 31
	111	+	(4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT); 32
	112	+	(5) 5-methoxy-3, 4-methylenedioxy amphetamine; 33
	113	+	(6) 4-bromo-2, 5-dimethoxyamphetamine; 34 25.232.15 4 35
	114	+	Underscores indicate new language.
	115	+	Overstrikes indicate deleted language.
	116	+	(7) 4-methoxyamphetamine; 1
	117	+	(8) 4-methoxymethamphetamine; 2
	118	+	(9) 4-methyl-2, 5-dimethoxyamphetamine; 3
	119	+	(10) Hashish and hash oil; 4
	120	+	(11) Ibogaine; 5
	121	+	(12) Lysergic acid diethylamide; 6
	122	+	(13) Mescaline; 7
	123	+	(14) N-ethyl-3-piperidyl benzilate; 8
	124	+	(15) N-methyl-3-piperidyl benzilate; 9
	125	+	(16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP); 10
	126	+	(17) Peyote, except that when used as a sacramental in services of the Native American 11
	127	+	church in a natural state which is unaltered except for drying or curing and cutting 12
	128	+	or slicing, it is hereby excepted; 13
	129	+	(18) Psilocybin; 14
	130	+	(19) Psilocyn; 15
	131	+	(20) Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in 16
	132	+	§ 38-35-1; in a drug product approved by the United States Food and Drug 17
	133	+	Administration; or marijuana in its natural and unaltered state; including any 18
	134	+	compound, except nabilone or compounds listed under a different schedule, 19
	135	+	structurally derived from 6,6Ν dimethyl-benzo[c]chromene by substitution at the 20
	136	+	3-position with either alkyl (C3 to C8), methyl cycloalkyl, or adamantyl groups, 21
	137	+	whether or not the compound is further modified in any of the following ways: 22
	138	+	(a) By partial to complete saturation of the C-ring; or 23
	139	+	(b) By substitution at the 1-position with a hydroxyl or methoxy group; or 24
	140	+	(c) By substitution at the 9-position with a hydroxyl, methyl, or methylhydoxyl 25
	141	+	group; or 26
	142	+	(d) By modification of the possible 3-alkyl group with a 1,1Ν dimethyl moiety, a 27
	143	+	1,1Ν cyclic moiety, an internal methylene group, an internal acetylene 28
	144	+	group, or a terminal halide, cyano, azido, or dimethylcarboxamido group. 29
	145	+	Some trade and other names: JWH -051; JWH-057; JWH-133; JWH-359; HHC; AM-30
	146	+	087; AM-411; AM-855, AM-905; AM-906; AM-2389; HU-210; HU-211; HU-243; 31
	147	+	HU-336; 32
	148	+	(21) 3, 4, 5-trimethoxy amphetamine; 33
	149	+	(22) 3, 4-methylenedioxy amphetamine; 34
	150	+	(23) 3-methoxyamphetamine; 35 25.232.15 5 35
	151	+	Underscores indicate new language.
	152	+	Overstrikes indicate deleted language.
	153	+	(24) 2, 5-dimethoxyamphetamine; 1
	154	+	(25) 2-methoxyamphetamine; 2
	155	+	(26) 2-methoxymethamphetamine; 3
	156	+	(27) 3-methoxymethamphetamine; 4
	157	+	(28) Phencyclidine; 5
	158	+	(29) 3, 4-methylenedioxymethamphetamine (MDMA); 6
	159	+	(30) 3, 4-methylenedioxy-N-ethylamphetamine; 7
	160	+	(31) N-hydroxy-3, 4-methylenedioxyamphetamine; 8
	161	+	(32) 4-methylaminorex (also known as 2-Amino-4-methyl/x-5-phenyl-2-oxazoline); 9
	162	+	(33) 2,5 Dimethoxy-4-ethylamphetamine; 10
	163	+	(34) N,N-Dimethylamphetamine; 11
	164	+	(35) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; 12
	165	+	(36) Aminorex; 13
	166	+	(37) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-14
	167	+	oxazolamine; 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine); 15
	168	+	(38) Cathinone and other variations, defined as any compound, material, mixture, 16
	169	+	preparation or other product unless listed in another schedule or an approved FDA 17
	170	+	drug, structurally derived from 2-aminopropan-1-one by substitution at the 1-18
	171	+	position with either phenyl, naphthyl, or thiophene ring systems, whether or not 19
	172	+	the compound is further modified in any of the following ways: 20
	173	+	(a) By substitution in the ring system to any extent with alkyl, alkylenedioxy, 21
	174	+	alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further 22
	175	+	substituted in the ring system by one or more other univalent substitutents; 23
	176	+	(b) By substitution at the 3-position with an acyclic alkyl substituent; or 24
	177	+	(c) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 25
	178	+	methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a 26
	179	+	cyclic structure. 27
	180	+	Some trade or other names: methcathinone, 4 -methyl-N-methylcathinone 28
	181	+	(mephedrone); 3,4 -methylenedioxy-N-methylcathinone (methylone); 3,4 -29
	182	+	methylenedioxypyrovalerone (MDPV); Naphthylpyrovalerone (naphyrone); 4 -30
	183	+	flouromethcathinone (flephedrone); 4-methoxymethcathinone (methedrone; Bk -31
	184	+	PMMA); Ethcathinone (N -Ethylcathinone); 3,4-methylenedioxyethcathinone 32
	185	+	(ethylone); Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N -33
	186	+	dimethylcathinone (metamfepramone); Alpha -pyrrolidinopropiophenone (alpha-34
	187	+	PPP); 4 -methoxy-alpha-pyrrolidinopropiophenone (MOPPP); 3,4 -35 25.232.15 6 35
	188	+	Underscores indicate new language.
	189	+	Overstrikes indicate deleted language.
	190	+	methylenedioxyalphapyrrolidinopropiophenone (MDPPP); Alpha -1
	191	+	pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone; 4Ν-Methyl-alpha-2
	192	+	pyrrolidinobutiophenone (MPBP); Methyl -α-pyrrolindinopropiophenone (MPPP); 3
	193	+	Methyl-α-pyrrolidino-hexanophenone (MPHP); Buphedrone; Methyl -N-4
	194	+	ethylcathinone; Pentedrone; Dimethylmethcathinone (DMMC); 5
	195	+	Dimethylethcathinone (DMEC); Methylenedioxymethcathinone (MDMC); 6
	196	+	Pentylone; Ethylethcathinone; Ethylmethcathinone; Fluoroethcathinone; methyl -7
	197	+	alpha-pyrrolidinobutiophenone (MPBP); Methylecathinone (MEC); Methylenedioxy -8
	198	+	alpha-pyrrolidinobutiophenone (MDPBP); Methoxymethcathinone (MOMC); 9
	199	+	Methylbuphedrone (MBP); Benzedrone (4 -MBC); Dibutylone (DMBDB); 10
	200	+	Dimethylone (MDDMA); Diethylcathinone; Eutylone (EBDB); N -ethyl-N-11
	201	+	Methylcathinone; N -ethylbuphedrone, 1 -(1,3-benzodioxol-5-yl)2-12
	202	+	(ethylamino)pentan-1-one (N -Ethylpentylone); 4' -Methyl-alpha-13
	203	+	pyrrolidinopropiophenone (4 -MEPPP, MPPP or MαPPP); alpha -14
	204	+	Pyrrolidinobutiophenone (α ;-PBP); 1 -(1,3-benzodioxol-5-yl)-2-(tert-15
	205	+	butylamino)propan-1-one (Tertylone); 1 -(1,3-benzodioxol-5-yl)-2-16
	206	+	(ethylamino)hexan-1-one (N-ethyl Hexylone); 1 -(1,3-benzodioxol-5-yl)-2-17
	207	+	(methylamino)pntan-1-one (Pentylone); N -ethylhexedrone (α 18
	208	+	ethylaminohexanophenone); alpha -pyrrolidinohexanophenone (α-PHP); 4-methyl-19
	209	+	alpha-ethylaminopentiophenone (4 -MEAP); 4′ -methyl-alpha-20
	210	+	pyrrolidinohexiophenone (MPHP); alpha -pyrrolidinoheptaphenone (PV8); 4′ -21
	211	+	chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP); Alpha-PIHP (4-methyl-22
	212	+	1-phenyl-2-(pyrrolindin-1-yl)pentan-1-one; 23
	213	+	(39) 2,5-Dimethoxy-4-ethylamphetamine (DOET); 24
	214	+	(40) Alpha-ethyltryptamine; 25
	215	+	(41) 4-Bromo-2,5-dimethoxy phenethylamine; 26
	216	+	(42) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7); 27
	217	+	(43) 1-(3-trifluoromethylphenyl) piperazine (TFMPP); 28
	218	+	(44) Alpha-methyltryptamine (AMT); 29
	219	+	(45) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); 30
	220	+	(46) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); 31
	221	+	(47) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is 32
	222	+	not listed as a controlled substance in another schedule, is not an FDA-approved 33
	223	+	drug, and contains any quantity of the following substances, their salts, isomers 34
	224	+	(whether optical, positional, or geometric), homologues, modifications of the indole 35 25.232.15 7 35
	225	+	Underscores indicate new language.
	226	+	Overstrikes indicate deleted language.
	227	+	ring by nitrogen heterocyclic analog substitution or nitrogen heterocyclic analog 1
	228	+	substitution of the phenyl, benzyl, naphthyl, adamantly, cyclopropyl, cumyl, or 2
	229	+	propionaldehyde structure, and salts of isomers, homologues, and modifications, 3
	230	+	unless specifically excepted, whenever the existence of these salts, isomers, 4
	231	+	homologues, modifications, and salts of isomers, homologues, and modifications is 5
	232	+	possible within the specific chemical designation: 6
	233	+	(a) Naphthoylindoles. Any compound containing a 2 -(1- naphthoyl)indole or 3-7
	234	+	(1-naphthoyl)indole structure with substitution at the nitrogen atom of the 8
	235	+	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 9
	236	+	1-(N-methyl-2-piperidinhyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-10
	237	+	(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 11
	238	+	(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not 12
	239	+	further substituted on the indole ring to any extent and whether or not 13
	240	+	substituted on the naphthyl ring to any extent. 14
	241	+	Some trade or other names: JWH -015; 1-pentyl-3-(1-naphthoyl)indole 15
	242	+	(JWH-018); 1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-16
	243	+	naphthoyl)indole (JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole 17
	244	+	(JWH-081); 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); 1-[2-(4-18
	245	+	morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210; JWH-398; 19
	246	+	1-pentyl-3-(1-naphthoyl)indole (AM -678); 1 -(5-fluoropentyl)-3-(1-20
	247	+	naphthoyl)indole (AM-2201); WIN 55-212; JWH-004; JWH-007; JWH-009; 21
	248	+	JWH-011; JWH-016; JWH-020; JWH-022; JWH-046; JWH-047; JWH-048; 22
	249	+	JWH-049; JWH-050; JWH-070; JWH-071; JWH-072; JWH-076; JWH-079; 23
	250	+	JWH-080; JWH-082; JWH-094; JWH-096; JWH-098; JWH-116; JWH-120; 24
	251	+	JWH-148; JWH-149; JWH-164; JWH-166; JWH-180; JWH-181; JWH-182; 25
	252	+	JWH-189; JWH-193; JWH-198; JWH-211; JWH-212; JWH-213; JWH-234; 26
	253	+	JWH-235; JWH-236; JWH-239; JWH-240; JWH-241; JWH-258; JWH-262; 27
	254	+	JWH-386; JWH-387; JWH-394; JWH-395; JWH-397; JWH-399; JWH-400; 28
	255	+	JWH-412; JWH-413; JWH-414; JWH-415; JWH-424; AM-678; AM-1220; 29
	256	+	AM-1221; AM-1235; AM-2232, THJ-2201; 30
	257	+	(b) Naphthylmethylindoles. Any compound containing a 1H -indol-2-yl-(1-31
	258	+	naphthyl)methane or 1H -indol-3-yl-(1-naphthyl)methane structure with 32
	259	+	substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 33
	260	+	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-34
	261	+	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1 -(N-methyl-2-35 25.232.15 8 35
	262	+	Underscores indicate new language.
	263	+	Overstrikes indicate deleted language.
	264	+	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-1
	265	+	4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted 2
	266	+	on the indole ring to any extent and whether or not substituted on the 3
	267	+	naphthyl ring to any extent. 4
	268	+	Some trade or other names: JWH -175; JWH-184; JWH-185; JWH-192; 5
	269	+	JWH-194; JWH-195; JWH-196; JWH-197; JWH-199; 6
	270	+	(c) Phenylacetylindoles. Any compound containing a 2-phenylacetylindole or 3-7
	271	+	phenylacetylindole structure with substitution at the nitrogen atom of the 8
	272	+	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 9
	273	+	1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, cyanoalky, 1-10
	274	+	(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 11
	275	+	(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not 12
	276	+	further substituted on the indole ring to any extent and whether or not 13
	277	+	substituted on the phenyl ring to any extent. 14
	278	+	Some trade or other names: 1 -cyc lohexylethyl-3-(2-15
	279	+	methoxyphenylacetyl)indole (SR -18); 1 -cyclohexylethyl-3-(2-16
	280	+	methoxyphenylacetyl)indole (RCS -8); 1 -pentyl-3-(2-17
	281	+	methoxyphenylacetyl)indole (JWH -250); 1 -pentyl-3-(2-18
	282	+	chlorophenylacetyl)indole (JWH-203); JWH-167; JWH-201; JWH-202; JWH-19
	283	+	204; JWH-205; JWH-206; JWH-207; JWH-208; JWH-209; JWH-237; JWH-20
	284	+	248; JWH-249; JWH-251; JWH-253; JWH-302; JWH-303; JWH-304; JWH-21
	285	+	305; JWH-306; JWH-311; JWH-312; JWH-313; JWH-314; JWH-315; JWH-22
	286	+	316; Cannabipiperidiethanone; 23
	287	+	(d) Benzoylindoles. Any compound containing a 2 -(benzoyl)indole or 3-24
	288	+	(benzoyl)indole structure with substitution at the nitrogen atom of the 25
	289	+	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 26
	290	+	1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1-27
	291	+	(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl, 28
	292	+	(tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl group, whether or not 29
	293	+	further substituted on the indole ring to any extent and whether or not 30
	294	+	substituted on the phenyl ring to any extent. 31
	295	+	Some trade or other names: 1 -(5-fluoropentyl)-3-(2-iodobenzoyl)indole 32
	296	+	(AM-694); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline 33
	297	+	(WIN 48,098); 1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4); AM-630; 34
	298	+	AM-661; AM-2233; AM-1241; 35 25.232.15 9 35
	299	+	Underscores indicate new language.
	300	+	Overstrikes indicate deleted language.
	301	+	(e) Naphthoylpyrroles. Any compound containing a 2-(1-naphthoyl)pyrrole or 3-1
	302	+	(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the 2
	303	+	pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 3
	304	+	cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 4
	305	+	cyanoalky, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-5
	306	+	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl 6
	307	+	group, whether or not further substituted on the pyrrole ring to any extent 7
	308	+	and whether or not substituted on the naphthyl ring to any extent. 8
	309	+	Some trade or other names: JWH -307; JWH-030; JWH-031; JWH-145; 9
	310	+	JWH-146; JWH-147; JWH-150; JWH-156; JWH-242; JWH-243; JWH-244; 10
	311	+	JWH-245; JWH-246; JWH-292; JWH-293; JWH-308; JWH-309; JWH-346; 11
	312	+	JWH-348; JWH-363; JWH-364; JWH-365; JWH-367; JWH-368; JWH-369; 12
	313	+	JWH-370; JWH-371; JWH-373; JWH-392; 13
	314	+	(f) Naphthylmethylindenes. Any compound containing a naphthylideneindene 14
	315	+	structure with substitution at the 3-position of the indene ring by an alkyl, 15
	316	+	haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-16
	317	+	piperidinyl)methyl, 2-(4-morpholinyl)ethyl, cyanoalky, 1 -(N-methyl-2-17
	318	+	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-18
	319	+	4-yl)methyl, benzyl, or halobenzyl group, whether or not further substituted 19
	320	+	on the indene ring to any extent and whether or not substituted on the 20
	321	+	naphthyl ring to any extent. 21
	322	+	Some trade or other names: JWH-171; JWH-176; JWH-220; 22
	323	+	(g) Cyclohexylphenols. Any compound containing a 2 -(3-23
	324	+	hydroxycyclohexyl)phenol structure with substitution at the 5-position of 24
	325	+	the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 25
	326	+	cycloalkylethyl, 1 -(N-methyl-2-piperidinyl)methyl, or 2 -(4-26
	327	+	morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-27
	328	+	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl 28
	329	+	group, whether or not substituted on the cyclohexyl ring to any extent. 29
	330	+	Some trade or other names: 5 -(1,1-dimethylheptyl)-2-[(1R,3S)-3-30
	331	+	hydroxycyclohexyl]-phenol (CP 47, 497 and homologues, which includes 31
	332	+	C8); cannabicyclohexanol; CP-55,490; CP-55,940; CP-56,667; 32
	333	+	(h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 33
	334	+	6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names: 34
	335	+	HU-210; 35 25.232.15 10 35
	336	+	Underscores indicate new language.
	337	+	Overstrikes indicate deleted language.
	338	+	(i) 2,3-Dihydro-5-methyl-3-(4-m orpholinylmethyl)pyrrolo[1,2,3 -de]-1,4-1
	339	+	benzoxazin-6-yl]-1-napthalenyl. Some trade or other names: WIN 55, 212-2
	340	+	2; 3
	341	+	(j) Substituted Acetylindoles. Any compound containing a 2-acetyl indole or 3-4
	342	+	acetyl indole structure substituted at the acetyl by replacement of the 5
	343	+	methyl group with a tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or 6
	344	+	propionaldehyde substituent whether or not further substituted on the 7
	345	+	tetramethylcyclopropyl, adamantyl, benzyl, cumyl, or propionaldehyde 8
	346	+	substituent to any extent and whether or not further substituted at the 9
	347	+	nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 10
	348	+	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-11
	349	+	morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-12
	350	+	morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, benzyl, or halobenzyl 13
	351	+	group whether or not further substituted on the indole ring to any extent. 14
	352	+	Some trade and or names: (1 -Pentylindol-3-yl)-(2,2,3,3-15
	353	+	tetramethylcyclopropyl)methanone (UR -144); (1-(5-fluoropentyl)indol-3-16
	354	+	yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (XLR -11); (1 -(2-17
	355	+	morpholin-4-ylethyl)-1H-indol-3-yl)-(2,2,3,3-18
	356	+	tetramethylcyclopropyl)methanone (A-796,260); 1-[(N-methylpiperidin-2-19
	357	+	yl)methyl]-3-(adamant-1-oyl)indole (AM -1248); 1 -Pentyl-3-(1-20
	358	+	adamantoyl)indole (AB-001 and JWH-018 adamantyl analog); AM-679; (1-21
	359	+	(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-22
	360	+	tetramethylcyclopropyl)methanone (FUB -144); 23
	361	+	(k) Substituted Carboxamide Indole. Any compound containing a 2 -carboxamide 24
	362	+	indole or 3-carboxamide indole structure substituted at the nitrogen of the 25
	363	+	carboxamide with a tetramethylcyclopropyl, naphthyl, adamantyl, cumyl, 26
	364	+	phenyl, or propionaldehyde substituent, whether or not further substituted 27
	365	+	on the tetramethylcyclopropyl, adamantyl, cumyl, naphthyl, phenyl, or 28
	366	+	propionaldehyde substituent to any extent and whether or not further 29
	367	+	substituted at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 30
	368	+	cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 -(N-methyl-2-31
	369	+	piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1 -(N-methyl-2-32
	370	+	pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-33
	371	+	4-yl)methyl, benzyl, or halobenzyl group whether or not further substituted 34
	372	+	on the indole ring to any extent. 35 25.232.15 11 35
	373	+	Underscores indicate new language.
	374	+	Overstrikes indicate deleted language.
	375	+	Some trade and other names: JWH -018 adamantyl carboxamide; STS -135; 1
	376	+	MN-18; 5-Fluoro-MN-18, 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-2
	377	+	pyrrolo[2,3-b]pyridine-3-carboxamide (5F -CUMYL-P7AICA) ; N -3
	378	+	(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F -4
	379	+	APINACA); methyl (2R)-2-[[1-(5-fluoropentyl)indazole-3-carbonyl]amino]-5
	380	+	3,3-dimethylbutanoate (5F-ADB); N-(1-amino-3-methyl-1-oxobutan-2-yl)-6
	381	+	1-(cyclohexylmethyl)indazole-3-carboxamide (AB -CHMINACA); 1 -(4-7
	382	+	cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (4-CN-8
	383	+	CUMYL-BUTINACA); N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-9
	384	+	(cyclohexylmethyl)indazole-3-carboxamide (ADB -CHMINACA or MAB -10
	385	+	CHMINACA); methyl (2S) -2-[[1-[4-fluorophenyl)methyl]indazole-3-11
	386	+	carbonyl]amino]-3,3-dimethylbutanoate (MDMB -FUBINACA); methyl 2-(1-12
	387	+	(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (MMB -13
	388	+	CHMICA); methyl (2S) -2-[[1-[4-fluorophenyl)methyl]indazole-3-14
	389	+	carbonyl]amino]-3-methylbutanoate (AMB -FUBINACA); Methyl 2 -(1-(5-15
	390	+	fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB); 16
	391	+	methyl 2 -(1-(5-fluoropentyl-1Hindole-3-carboxamido)-3,3-17
	392	+	dimethylbutaoate (5F-MDMB-PICA); methyl (S)-3,3-dimethyl-2-[(1-(pent-18
	393	+	4-enlindazole-3-carbonyl)amino]butanoate (MDMB -4en-PINACA); methyl 19
	394	+	2-(1-(4-fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate 20
	395	+	(4F-MDMB-BUTINACA); Ethyl 2 -(1-(5-fluoropentyl)-1H-indazole-3-21
	396	+	carboxamido)-3,3-dimethylbutanoate (5F-EDMB-PINACA); Methyl 2-(1-(5-22
	397	+	fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate S(5F -23
	398	+	MDMB-PICA); N -(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-24
	399	+	carboxamide (FUB-APINACA); 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-25
	400	+	1H-indazole-3-carboxamide (5F-CUMYL-PINACA); 26
	401	+	(l) Substituted Carboxylic Acid Indole. Any compound containing a 1H-indole-2-27
	402	+	carboxylic acid or 1H-indole-3-carboxylic acid substituted at the hydroxyl 28
	403	+	group of the carboxylic acid with a phenyl, benzyl, naphthyl, adamantyl, 29
	404	+	cyclopropyl, quinolinyl, isquinolinyl, cumyl, or propionaldehyde substituent 30
	405	+	whether or not further substituted on the phenyl, benzyl, naphthyl, 31
	406	+	adamantyl, cyclopropyl, cumyl, quinolinyl, isquinolinyl, or propionaldehyde 32
	407	+	substituent to any extent and whether or not further substituted at the 33
	408	+	nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, 34
	409	+	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-35 25.232.15 12 35
	410	+	Underscores indicate new language.
	411	+	Overstrikes indicate deleted language.
	412	+	morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-1
	413	+	morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group 2
	414	+	whether or not further substituted on the indole ring to any extent. 3
	415	+	Some trade and other names: Naphthalen-1-yl 1-(5-fluoropntyl)-1H-indole-4
	416	+	3-carboxylate (NM2201); 5
	417	+	(48) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI); 6
	418	+	(49) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); 7
	419	+	(50) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); 8
	420	+	(51) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C -C); 9
	421	+	(52) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C -I); 10
	422	+	(53) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C -T-2); 11
	423	+	(54) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C -T-4); 12
	424	+	(55) 2-(2,5-Dimethoxyphenyl)ethanamine (2C -H); 13
	425	+	(56) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); 14
	426	+	(57) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); 15
	427	+	(58) Substituted phenethylamine. Any compound, unless specifically exempt, listed as a 16
	428	+	controlled substance in another schedule or an approved FDA drug, structurally 17
	429	+	derived from phenylethan-2-amine by substitution on the phenyl ring in any of the 18
	430	+	following ways: by substitution with a fused methylenedioxy, fused furan, or fused 19
	431	+	tetrahydrofuran ring system; by substitution with two alkoxy groups; by 20
	432	+	substitution with one alkoxy and either one fused furan, tetrahydrofuran, or 21
	433	+	tetrahydropyran ring system; by substitution with two fused ring systems from any 22
	434	+	combination of the furan, tetrahydrofuran, or tetrahydropyran ring systems; 23
	435	+	whether or not the compound is further modified in any of the following ways: 24
	436	+	(a) By substitution on the phenyl ring by any halo, hydroxyl, alkyl, 25
	437	+	trifluoromethyl, alkoxy, or alkylthio groups; 26
	438	+	(b) By substitution on the 2-position by any alkyl groups; or 27
	439	+	(c) By substitution on the 2-amino nitrogen atom with acetyl, alkyl, dialkyl, 28
	440	+	benzyl, methoxybenzyl, or hydroxybenzyl groups. 29
	441	+	Some trade and other names: 2 -(2,5-dimethoxy-4-30
	442	+	(methylthio)phenyl)ethanamine (2C -T or 4 -methylthio-2,5-31
	443	+	dimethoxyphenethylamine); 1 -(2,5-dimethoxy-4-iodophenyl)-propan-2-amine 32
	444	+	(DOI or 2, 5 -Dimethoxy-4-iodoamphetamine); 1 -(4-Bromo-2,5-33
	445	+	dimethoxyphenyl)-2-aminopropane (DOB or 2,5 -Dimethoxy-4-34
	446	+	bromoamphetamine); 1 -(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine (DOC 35 25.232.15 13 35
	447	+	Underscores indicate new language.
	448	+	Overstrikes indicate deleted language.
	449	+	or 2,5-Dimethoxy-4-chloroamphetamine); 2-(4-bromo-2,5-dimethoxyphenyl)-N-1
	450	+	[(2-methoxyphenyl)methyl]ethanamine (2C -B-NBOMe; 25B -NBOMe or 2,5 -2
	451	+	Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine); 2 -4-iodo-2,5-3
	452	+	dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C -I-NBOMe; 25I-4
	453	+	NBOMe or 2,5 -Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine); N -(2-5
	454	+	Methoxybenzyl)-2-(3,4,5-trimethoxypheny (Mescaline -NBOMe or 3,4,5 -6
	455	+	trimethoxy-(2-methoxybenzyl)phenethylamine); 2 -(4-chloro-2,5-7
	456	+	dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (2C -C-NBOMe; 25C-8
	457	+	NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine); 2 -(7-9
	458	+	Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine (2CB-5-hemiFLY); 10
	459	+	2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine (2C-B-11
	460	+	FLY); 2 -(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-12
	461	+	yl)ethanamine (2C -B-butterFLY); -(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-13
	462	+	tetrahydrobenzo[1,2-b:4,5-bΝ]difuran-4-yl)-2-aminoethane (2C-B-FLY-NBOMe); 14
	463	+	1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine (bromo -15
	464	+	benzodifuranyl-isopropylamine or bromo-dragonFLY); -(2-Hydroxybenzyl)-4-iodo-16
	465	+	2,5-dimethoxyphenethylamine (2C -I-NBOH or 25I -NBOH); 5 -(2-17
	466	+	Aminoprpyl)benzofuran (5-APB); 6(2-Aminopropyl)benzofuran (6-APB); 5-(2-18
	467	+	Aminopropyl)-2,3-dihydrobenzofuran (5 -APDB); 6 -(2-Aminopropyl)-2,3,-19
	468	+	dihydrobenzofuran (6-APDB); para-methoxymethamphetamine (PMMA); 20
	469	+	(59) Substituted tryptamines. Any compound, unless specifically exempt, listed as a 21
	470	+	controlled substance in another schedule or an approved FDA drug, structurally 22
	471	+	derived from 2-(1H-indol-3-yl)ethanamine by mono - or di-substitution of the 23
	472	+	amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen 24
	473	+	atom in a cyclic structure whether or not the compound is further substituted at 25
	474	+	the alpha-position with an alkyl group or whether or not further substituted on the 26
	475	+	indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups. 27
	476	+	Some trade and other names: 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT); 4-28
	477	+	acetoxy-N,N-dimethyltryptamine (4-AcO-DMT or O-Acetylpsilocin); 4-hydroxy-N-29
	478	+	methyl-N-ethyltryptamine (4-HO-MET); 4-hydroxy-N,N-diisopropyltryptamine (4-30
	479	+	HO-DIPT); 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT); 31
	480	+	(60) Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB-13); 32
	481	+	(61) N-Adamantyl-1-pentyl-1H-Indazole-3-carboxamide (AKB 48); 33
	482	+	(62) 1-(4-Fluorophenyl)piperazine (pFPP); 34
	483	+	(63) 1-(3-Chlorophenyl)piperazine (mCPP); 35 25.232.15 14 35
	484	+	Underscores indicate new language.
	485	+	Overstrikes indicate deleted language.
	486	+	(64) 1-(4-Methoxyphenyl)piperazine (pMeOPP); 1
	487	+	(65) 1,4-Dibenzylpiperazine (DBP); 2
	488	+	(66) Isopentedrone; 3
	489	+	(67) Fluoromethamphetamine; 4
	490	+	(68) Fluoroamphetamine; 5
	491	+	(69) Fluorococaine; 6
	492	+	(70) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22); 7
	493	+	(71) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (5 Fluoro-PB-22); 8
	494	+	(72) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-9
	495	+	PINACA); 10
	496	+	(73) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-11
	497	+	carboxamide (5 Fluoro-AB-PINACA); 12
	498	+	(74) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-13
	499	+	carboxamide (AB-FUBINACA); 14
	500	+	(75) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide 15
	501	+	(ADB-PINACA (ADBICA)); 16
	502	+	(76) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-17
	503	+	carboxamide (5 Fluoro-ADB-PINACA (5 Fluoro-ADBICA)); 18
	504	+	(77) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-19
	505	+	carboxamide (ADB-FUBINACA); 20
	506	+	(78) N-(1-carbamoyl-2-methyl-propyl)-2-(5-fluoropentyl)-5-(4-fluorophenyl)pyrazole-21
	507	+	3-carboxamide (5-Fluoro-3,5-AB-PFUPPYCA); and 22
	508	+	(79) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine). 23
	509	+	Section 3. Whereas, this Act is necessary for the immediate preservation of the public peace, 24
	510	+	health, or safety, an emergency is hereby declared to exist, and this Act shall be in full force 25
	511	+	and effect from and after its passage and approval. 26